Eli Lilly: conclusive phase III trial on tirzepatide

(CercleFinance.com) - Eli Lilly has presented the detailed results of a three-year Phase III trial evaluating tirzepatide (Zepbound and Mounjaro).


The laboratory reports that this weekly treatment "significantly" reduced the risk of progression to type 2 diabetes in overweight or obese adults, with an average weight loss maintained at 22.9% over 176 weeks.

Ania Jastreboff, Director of the Yale Obesity Research Center, points out that 99% of treated participants remained diabetes-free after three years of treatment.

Eli Lilly adds that tirzepatide also improved glycemic control and cardiometabolic risk factors.

The results were published in The New England Journal of Medicine (NEJM) and recently presented at ObesityWeek 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.